For CBS with confirmed maternal past infection, defined as both IgG anti-RBD and anti-N above the positivity threshold of 700 Median Fluorescence Intensity (MFI), as defined by the manufacturer guidelines, we further tested CBS for SARS-CoV-2 specific IgA and IgM antibodies targeting RBD and N antigens19,20. The gene discussed is CD79A; the disease is infection.